Regulatory Focus March 24, 2023
By Ferdous Al-Faruque

The US Food and Drug Administration (FDA) plans to hold at least one public meeting and release several guidances on digital health technologies (DHT) to be used in drug clinical trials by the end of the year. While it has issued guidances on digital health products generally, there is still concern about whether such products are accurate and reliable enough to gather data for the drug development process.

As part of FDA’s commitment under the Prescription Drug User Fee Act (PDUFA VII), the agency published a framework on 23 March on how it plans to address long-standing questions on the use of DHTs in drug clinical trials.

The agency has established a steering committee with staff from its drug, device,...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Clinical Trials, Digital Health, FDA, Govt Agencies, Technology, Trends
Use AI to regulate AI, Google executive says
The Current State Of 521 FDA-Approved, AI-Based Medical Devices
Elon Musk’s Neuralink Wants To Put Chips In Our Brains — How It Works And Who Else Is Doing It
Over-the-Counter Hearing Aids — Using Regulatory Policy to Improve Public Health
FDA Updates Cybersecurity Guidance

Share This Article